Terry Forss, NP
Adult Health · Greenwood, INNPI 1790973790
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 177 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 25 manufacturers reported payments, led by AbbVie at 25.3% of the total. Reporting peaked in 2024 at $1,292 and has fallen 85.9% since, to $183 in 2025.
Across 177 payments — averaging $18.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$851
- Novo Nordisk$620
- AstraZeneca$594
- Lilly USA, LLC$246
- Boehringer Ingelheim$206
- Exact Sciences$145
- plus $700 from 19 others
What the payments were for
- Food & beverage$3,362100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 56 | $851 |
| Novo Nordisk | 36 | $620 |
| AstraZeneca | 14 | $594 |
| Lilly USA, LLC | 17 | $246 |
| Boehringer Ingelheim | 9 | $206 |
| Exact Sciences | 7 | $145 |
| Pfizer | 8 | $143 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $90 |
| Tempus AI, Inc | 3 | $69 |
| Abbott | 3 | $65 |
| Edwards Lifesciences | 2 | $48 |
| Idorsia Pharmaceuticals US Inc | 3 | $42 |
| Dynavax Technologies Corporation | 2 | $40 |
| Halozyme Inc | 2 | $34 |
| Dexcom, Inc. | 1 | $21 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $19 |
| Axsome Therapeutics, Inc. | 1 | $19 |
| Merck | 1 | $17 |
| Antares Pharma, Inc. | 1 | $15 |
| GSK | 1 | $14 |
| Otsuka America Pharmaceutical, Inc. | 1 | $13 |
| Amgen | 1 | $13 |
| Astellas Pharma US Inc | 1 | $13 |
| Sanofi-aventis U.S. LLC | 1 | $13 |
| Mylan Specialty L.p. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AIRSUPRA$125
How this compares
$3,362 in reported general payments places this provider in the 85th percentile of 391 adult health providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 42 | $44,877 |
| VraylarCariprazine Hcl | 13 | $35,972 |
| MounjaroTirzepatide | 27 | $33,938 |
| OzempicSemaglutide | 32 | $33,899 |
| EliquisApixaban | 18 | $29,257 |
| FarxigaDapagliflozin Propanediol | 15 | $14,305 |
| Breo ElliptaFluticasone/Vilanterol | 17 | $10,801 |
| Famotidine | 25 | $1,994 |
| Buspirone Hcl | 80 | $1,811 |
| Duloxetine Hcl | 51 | $1,206 |
| Omeprazole | 83 | $1,074 |
| Atorvastatin Calcium | 108 | $981 |
| Rosuvastatin Calcium | 80 | $920 |
| Gabapentin | 60 | $917 |
| Hydroxyzine Hcl | 38 | $879 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $206 | $44,87742 claims |
| AbbVieVraylar | $851 | $35,97213 claims |
| Lilly USA, LLCMounjaro | $246 | $33,93827 claims |
| Novo NordiskOzempic | $620 | $33,89932 claims |
| PfizerEliquis | $143 | $29,25718 claims |
| AstraZenecaFarxiga | $594 | $14,30515 claims |
| GSKBreo Ellipta | $14 | $10,80117 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 391 adult health providers in Indiana.
Other adult health in Greenwood
- Jennifer BerryIndianapolis$50K
- Tajuana DavisZionsville$31K
- Patricia Damron-RobinsonMerrillville$20K
- Terry RidgeCarmel$20K
- Kristine StarcevichMerrillville$19K
- Jolyn Holliday VezaGreenfield$17K
- Anna MatulewiczMishawaka$14K
- Ludmila Pichugena-EmersonMiddlebury$14K
- Vincent SmithMerrillville$13K
- Lisa DankoCrown Point$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.